GSK Partners with Avalon Ventures to Back Drug-Discovery Startups
(Reuters) - GlaxoSmithKline said on Monday it will partner with venture capital firm Avalon Ventures in a deal worth up to $495 million to fund as many as 10 drug-discovery startups over the next three years.
23 April 2013•2 mins read
